Actively Recruiting
Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)
Led by Fujian Cancer Hospital · Updated on 2025-09-11
43
Participants Needed
1
Research Sites
210 weeks
Total Duration
On this page
Sponsors
F
Fujian Cancer Hospital
Lead Sponsor
J
Jiangsu Cancer Institute & Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Locally advanced cervical cancer (LACC) remains a significant global health concern with limited treatment options. Recent advancements suggest that using neoadjuvant anti-PD-1 inhibitors in combination with chemotherapy, followed by radical surgery, may be an effective treatment strategy for patients with PD-L1-positive LACC. This study aims to evaluate the efficacy and safety of preoperative treatment with iparomlimab and tuvonralimab-a bifunctional PD-1/CTLA-4 dual blocker-combined with chemotherapy for LACC.
CONDITIONS
Official Title
Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent
- Age 18 to 70 years
- Adequate organ function and ECOG performance status 0 to 1
- No systemic therapy at enrollment
- FIGO 2018 stage IB3, IIA2, or IIIC1r
- Histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix
- Measurable lesions per RECIST v1.1
- Willing to have blood and tumor tissue tested
- Able to follow study visits, schedule, and medical exams
- Normal major organ function with specified blood and biochemical tests
- Willing and able to comply with treatment and research procedures
You will not qualify if you...
- History of other cancers within the past 3 years
- Participation in other clinical trials simultaneously
- Active autoimmune disease requiring systemic treatment
- Uncontrolled infection requiring systemic therapy
- History of allogeneic tissue or solid organ transplant
- Serious illnesses such as severe mental disorders, cardiac disease, coagulation disorders, or digestive diseases
- Active hepatitis B, hepatitis C, or HIV infection
- Pregnant or breastfeeding
- Drug or alcohol abuse
- Unable or unwilling to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014
Actively Recruiting
Research Team
Y
Yang Sun, PHD
CONTACT
J
Jie Lin, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here